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Abstract: An ideal animal model for the study of a human disease is one which utilizes a 
route of infection that mimics the natural transmission of the pathogen; the ability to obtain 
disease  with  an  infectious  dose  equivalent  to  that  causing  disease  in  humans;  as  well 
having a disease course, morbidity and mortality similar to that seen with human disease. 
Additionally, the animal model should have a mode(s) of transmission that mimics human 
cases. The development of small animal models for the study of monkeypox virus (MPXV) 
has been quite extensive for the relatively short period of time this pathogen has been 
known, although only a few of these models have been used to study anti-poxvirus agents. 
We will review those MPXV small animal models that have been developed thus far for 
the study of therapeutic agents. 
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1. Introduction 
An ideal animal model for the study of a human disease is one which utilizes a route of infection 
that mimics the natural transmission of the pathogen; the ability to obtain disease with an infectious 
dose equivalent to that causing disease in humans; as well having a disease course, morbidity and 
mortality  similar  to  that  seen  with  human  disease.  Additionally,  the  animal  model  should  have  a 
mode(s) of transmission that mimics human cases. Factors which subsequently allow more detailed 
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inferences about disease pathogenesis include the availability of reagents to evaluate host innate and 
adaptive immune responses to the pathogen, and histopathological changes in the host which result 
from infection or the host response to infection. These findings can then be compared to what is known 
of human disease. The utility of a small animal model of human disease for study of therapeutic 
efficacy  is  augmented  when  large  numbers  of  animals  are  available  for  use  in  appropriately,  
well-powered studies. Even if all aspects of an animal model of disease are not completely faithful to 
what is known of human disease, important information regarding therapeutic efficacy can be gleaned 
from their use in ―pre-clinical‖ studies.  
The  published  literature  on  clinical  manifestations  of  systemic  human  orthopoxvirus  disease  is 
derived from historic literature descriptions of human smallpox and more recent descriptions of human 
monkeypox disease. The clinical-descriptive literature on human monkeypox is expected to grow in 
the next five years, as data acquisition and analysis from an ongoing study in the Democratic Republic 
of  Congo  is  finalized.  Currently  available  literature  is  largely  derived  from  WHO-sponsored 
surveillance efforts in West Africa and the Congo Basin in the 1980s, after the first recognition of 
human disease in these areas, and subsequent analyses of public health response data and human 
research studies following the introduction of West African clade virus into the U.S. in 2003. Human 
monkeypox, as described through the active surveillance and case ascertainment studies sponsored by 
WHO in the 1980s, was depicted as resembling discrete ordinary smallpox. In natural human infection, 
exposure leading to infection is believed to occur via a respiratory route, with subsequent progressive 
viremias/lymphemia,  ultimately  leading  to  seeding  of  the  skin  to  generate  a  generalized  rash. 
Percutaneous exposure, also leading to generalized rash formation, has also been described for both 
viral  infections.  The  disease  pathogenesis  has  been  conjectured  and  modeled  largely  from  animal 
studies; initial models were using ectromelia infection of mice; some kinetic observations of virus 
shedding and viremia have been made in human studies of smallpox and monkeypox. The time course 
of disease is generally thought to include an asymptomatic phase of 10–12 days, during which time the 
virus initially enters the host, replicates, seeds reticuloendothelial organs, replicates, then spreads via 
the bloodstream (inducing a febrile response) which is the first symptomatic hallmark of disease. The 
fever  is  usually  described  as  occurring  10–12  days  post  initial  exposure/infection.  The  range  has  
been 7–17 days. Fever is accompanied by other symptoms, including headache, backache, myalgias, 
and or abdominal pain. Two to three days following the fever, rash develops—initially presenting as a 
macular, then papular, then vesicular and pustular eruption. Scabbing then begins. Each stage of rash 
lasts 1–2 days. Approximately 2–3 weeks post initial symptoms, scabs begin to separate from the skin. 
Death and disease severity have had some correlation with rash burden in epidemiologic studies of 
hospitalized  smallpox  patients.  Severe  outcomes  are  more  frequent  in  unvaccinated,  younger  age 
groups; death occurs within the first week of illness in cases with hemorrhagic manifestations, and 
during the second or third week of illness in ―ordinary‖ cases. In the human monkeypox cases studied 
in Zaire/DRC between 1981–1986, of the 33 deaths among 338 patients, all occurred in unvaccinated 
children less than eight years of age. Death occurred during the first week of illness in 21%, the second 
week in 52%, and the third week of illness in the remaining 27% [1].  
The development of small animal models for the study of monkeypox virus (MPXV) has been quite 
extensive for the relatively short period of time this pathogen has been known. Initial animal models 
were designed to address natural history in potential or surrogate reservoir host species, as well as Viruses 2010, 2                         
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studies of disease in primates. Routes of exposure were designed to evaluate disease if respiratory or 
percutaneous exposures occurred, or in some cases to simply address whether virus would replicate in 
the animal model system. Factors that influence the outcome of a challenge study include the age of 
the animal at time of infection, inoculation route used, and the viral dosage given. Additionally, the 
strain of MPXV (currently delineated as belonging to Congo Basin clade or West African clade) used 
in the study may influence the disease severity.  
2. Animal Models Using Monkeypox Virus as a Challenge Virus (Table 1) 
Guinea pigs and golden hamsters were found to be relatively resistant to MPXV (West African 
clade Copenhagen strain) infection by multiple routes. Guinea pigs were challenged via an intracardial, 
intranasal (IN), oral or foot pad (FP) inoculation with no observable symptoms of disease except  
for  edema  at  the  FP  inoculation  site.  Golden  hamsters  were  also  resistant  to  MPXV  infection  
via  several  routes  of  infection  with  no  observable  signs  of  disease,  even  with  large  dosages  of  
virus (1.5–5.9 × 10
7) [2]. 
Rabbits  have  also  been  considered  as  a  possible  animal  model  for  the  study  of  MPXV  [2–3]; 
susceptibility depended greatly on the method of inoculation and the age of the animals. In adult 
rabbits challenged with MPXV (West African clade Copenhagen strain) via an oral inoculation, no 
signs of disease were seen. However, if virus was delivered by intravenous route, acute illness was 
observed with generalized rash. Young rabbits (10 days old) inoculated via IN or oral route developed 
severe illness; two day old rabbits were highly susceptible to infection by intracutaneous inoculation or 
skin scarification [4]. The intracutaneous route led to the development of discrete white translucent 
lesions. Another study found that intracerebral inoculation was 100% fatal and that intratesticular or 
intracorneal inoculation with MPXV was also pathogenic in rabbits [5].  
Several rat species including white rats, cotton rats and multimammate rats have been challenged 
with MPXV. Adult white rats inoculated with 10
1 to 10
3 plaque forming units (pfu) of West African 
MPXV  were  not  susceptible  to  infection  with  intravenous,  IN,  or  cutaneous  routes  of  infection. 
However, newborn white rats (1–3 days old) developed adynamia leading to death in 5–8 days when 
challenged with MPXV intranasally [2]. Cotton rats and multimammate rats were both found to be 
highly  susceptible  to  MPXV  infection.  When  cotton  rats  were  challenged  with  10
5  pfu  via  an 
intravenous route of infection, 100% mortality was seen 4–5 days post infection (p.i.). The infection 
was characterized by difficulty breathing, cough, sneezing, cyanosis, rhinitis, purulent conjunctivitis, 
and  progressive  emaciation.  An  IN  MPXV  challenge  in  cotton  rats  caused  50%  mortality  with  a 
clinical picture such as that seen with the intravenous route [6,7]. Multimammate rats were highly 
sensitive to both IN and intraperitoneal (IP) inoculation [7,8].  
Marennikova  et  al.  challenged  adult  common  squirrels  (Sciurus  vulgaris)  with  10
6  pfu  of  
MPXV  Z-249  (Congo  Basin  clade)  via  IN,  oral  or  scarification  routes  of  infection  [9].  Disease 
progression  occurred  earlier  in  animals  infected  IN  or  orally  than  those  animals  infected  via  a 
scarification route. Skin lesions did not develop on any animals; symptoms of disease included fever, 
inactivity, inappetence, rhinitis, cough and difficulty breathing. Infection was 100% lethal by day 7 or 
8  p.i.  regardless  of  inoculation  route.  Shelukhina  et  al.  challenged  six  African  squirrel  species 
(including  members  of  the  genera  Funisciurus,  Protexerus  and  Heliosciurus)  with  Congo  Basin Viruses 2010, 2                         
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MPXV via an IN infection (10
5 or 10
6 pfu/0.1 mL) [10]. All squirrel species were highly susceptible to 
Congo Basin MPXV challenge and developed an acute, generalized infection that was 100% lethal. 
However, some varying degree of susceptibility in the different squirrel species was seen with lesser 
dosages of virus. Cutaneous inoculation of squirrels resulted in a thick, red papule at the inoculation 
site. Skin lesions (restricted to non-fur-bearing areas of the skin or at the borders of the skin and 
mucous membranes of the nose and lip) occurred in only a few squirrels that had been infected by the 
oral or IN route with small (nonlethal) doses of virus. Most often the rash appeared in the later stages 
of disease (16–25 days p.i.). Transmission studies were also conducted with squirrels and authors 
found that infected animals were able to transmit the disease to naïve animals via airborne and direct 
contact [10]. 
Ground  squirrels  (Spermophilus  tridecemlineatus)  are  very  susceptible  to  MPXV  infection.  
Tesh et al. challenged adult ground squirrels with the West African MPXV clade either IP or IN  
with 10
5.1 pfu [11]. In both groups, symptoms of disease included anorexia and lethargy within 4–5 
days  of  infection,  with  no  other  observable  symptoms.  Weight  loss  was  not  measured  for  these 
animals. Animals in the IP group died within 6–7 days p.i.; those IN challenged all died within 8–9 
days. A follow-up study compared the pathogenesis of the two MPVX clades in the ground squirrel 
model [12]. Inoculation of 100 pfu by a subcutaneous route of infection was 100% lethal for both 
MPXV clades. However, the authors noted that the onset of severe respiratory distress was more rapid 
and uniform for the Congo Basin MPXV challenged animals. Additionally, animals challenged with 
the Congo Basin MPXV began to die earlier than West African challenged animals. However, LD50 
values were similar for the two strains using the ground squirrel MPXV model (0.35 pfu for Congo 
Basin and 0.46 pfu for West African MPXV).  
Prairie dogs have also been looked at as a possible MPXV animal model. Xiao et al. challenged 
prairie dogs with 10
5.1 pfu of West African MPXV via an IP or IN route of infection and observed 
100%  and 60%  mortality, respectively  [13].  Hutson  et  al.  challenged  prairie  dogs  with  either the 
Congo Basin or West African MPXV (10
4.5 pfu) via an IN or scarification route of infection [14]. 
Animals were asymptomatic until days 9–12 when a generalized rash was observed on challenged 
animals. Signs of disease included lethargy, inappetence, nasal discharge, respiratory distress, and 
diarrhea;  morbidity  was  noticeably  more  for  the  Congo  Basin  MPXV  challenged  animals  as  was 
mortality. A follow-up study found the LD50 for the prairie dog MPXV model is approximately a 
hundred-times lower for the Congo Basin clade compared to the West African clade (5.9 × 10
3 and 
1.29 × 10
5, respectively) [15], utilizing an IN route of infection. Weight loss occurred in 2/4 West 
African MPXV challenged dosage groups and 3/4 Congo Basin MPXV challenged dosage groups; for 
both viral strains the highest percent weight loss calculated occurred in the highest viral inoculum 
group. A trend of increasing viral titers in oropharyngeal swabs with increasing viral inoculums dose 
was  apparent  for  both  MPXV  strains,  and  when  all  mean  values  were  combined,  Congo  Basin 
challenged animals had statistically higher levels of virus. Furthermore, the duration of MPXV DNA 
and viral shedding tended to occur earlier, attain higher levels, and persist longer for Congo Basin 
challenged animals. Symptoms were also more numerous and severe for Congo Basin MPXV infected 
prairie dogs.  
Schultz et al. challenged African dormice, Graphiuris kelleni, with 1.4 × 10
4 pfu of a Congo Basin 
clade of MPXV via FP route and observed 92% mortality [16]. The authors further developed the Viruses 2010, 2                         
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model  by  infecting  dormice  with  various  dosages  of  Congo  Basin  MPXV  by  the  IN  route  and 
calculated the LD50 as 12 pfu. Animals became symptomatic at day 3 (conjunctivitis and dehydration), 
and animals that succumbed to disease had a mean time to death of 7.9 ± 1 to 12.3 ± 5 days (depending 
on dose). Morbidity for those animals that succumbed to disease included decreased activity, hunched 
posture, unkempt hair coat, dehydration, and conjunctivitis; lesions did not develop on any animals. 
Weight loss was highest with 2,000 pfu (the highest dosage given), but also was seen in animals given 
200 or 20 pfu. Weight loss was not observed in the lowest dosage groups (2 and 0.2 pfu). Disease 
pathogenesis was described as localized inflammation, viral replication and hemorrhage in the nasal 
mucosa, followed by dissemination around day 3 with subsequent necrosis of liver, spleen, lung and 
gastrointestinal tract tissues. When the West African strain of MPXV was used to challenge dormice 
by an IN infection, similar days until death and mortality rates were seen as the Congo Basin MPXV 
challenged animals. 
As is the case for many pathogens, mice have been utilized numerous times for the study of MPXV. 
Results have varied greatly depending on the type of mice used (i.e., wild strains or laboratory strains). 
In early studies [2,4] white mice were challenged via intracerebral, IN, IP, FP, oral or intradermal (ID) 
inoculation with a West African strain of MPXV and found to be highly sensitive to most inoculation 
routes. Intracerebral inoculation was 100% fatal in adult white mice as was IN inoculation of suckling 
mice [4]. Inoculation in eight day old mice via the FP, IP, or IN route resulted in 100% mortality; ID or 
oral inoculation caused 50% and 40% mortality, respectively. Oral inoculation of 12 day old white 
mice  only  caused  14%  mortality;  however  IN  inoculation  in  15  day  old  animals  led  to  100%  
mortality [2]. Inbred laboratory mouse strains have also been studied by several groups. Hutson et al. 
compared the two clades of virus (10
5 pfu) in immunocompetent BALB/c and C57BL/6 laboratory 
mouse strains via an IN or FP route of infection [17]. Localized signs in the FP challenged animals 
included edema at the inoculation site, while the Congo Basin IN route of infection led to weight loss. 
However, symptoms were minimal and all animals survived infection. Osorio et al. compared both 
clades of virus by an IP inoculation in either BALB/c or severe combined immune deficient (SCID) 
BALB/c mice [18]. Biophotonic imaging was used to visualize the disease progression. BALB/c mice 
developed rough coats, and decreased activity but cleared infection within 10 days p.i. In contrast, 
SCID BALB/c mice developed similar symptoms, but resulted in 100% mortality by day 9 p.i. (Congo 
Basin MPXV) or day 11 p.i. (West African MPXV). Stabenow et al. utilized a laboratory mouse  
strain lacking STAT1 (C57BL/6stat-/-), an important protein involved in Type I and Type II IFN 
signaling  [19].  Mice  were  challenged  with  dosages  between  4.7  to  4,700  pfu  via  an  IN  route  of 
infection. Weight loss was seen with all dosages given except for the lowest (4.7 pfu). Mortality 
occurred at 25–50% at the 47 pfu dose (12–21 days p.i.); 100% mortality occurred by day 9 p.i.  
with  the  highest  dose  given  (4,700  pfu).  The  calculated  LD50  for  the  Congo  Basin  clade  in  the 
C57BL/6stat-/- mice was 213 and 47 pfu for females and males, respectively. Americo et al. screened 
38 inbred mouse strains and identified three that are highly susceptible to MPXV [20]. Of these three 
strains, the CAST/EiJ was developed as a model. Signs of morbidity in moribund animals included 
ruffled fur, hunched posture, and lethargy; no animals developed lesions. Animals challenged with the 
highest dosages by an IN route (10
5 or 10
6 pfu Congo Basin MPXV) lost up to 28% of the starting 
body weight and 100% died between days 5–8. Animals challenged with 10
4 pfu all died between days 
8–10. Animals challenged with 10
3 pfu had an even longer delay in weight loss and death and 40% of Viruses 2010, 2                         
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the animals recovered. No animals perished in the 10
2 pfu challenge group. The calculated LD50 for the 
Congo Basin clade in the CAST/EiJ mice given an IN challenge was 680 pfu. Animals were found to 
be even more sensitive with an IP Congo Basin MPXV infection and the calculated LD50 was 14 pfu. 
Challenging mice with 10
5 or 10
6 pfu of a West African MPXV strain resulted in rapid weight loss  
and 100% mortality by day 8 p.i. Lower dosages of West African MPXV resulted in less weight loss 
and lower amounts of death than what was observed for the Congo Basin MPXV; the calculated LD50 
was 7,600 pfu, more than a log higher than for the Congo Basin clade.  
3. Antiviral Protection in Small Animals Challenged With Monkeypox Virus  
To  date,  four  MPXV  small  animal  models  have  been  used  for  the  testing  of  antiviral  drugs 
Cidofovir, CMX001 and ST246 (tecovirimat). Herein we will summarize those studies, efficacy data, 
and discuss the advantages, and limitations, of the animal models used.  
Sbrana  et  al.  utilized  ground  squirrels  to  test  the  efficacy  of  ST-246  against  a  MPXV  
challenge [21]. The authors used 100 pfu of MPX-ZAI-1970 (200 × LD50) via a subcutaneous route of 
inoculation. Squirrels (8–9 per group) were divided into five treatment groups; drug was given either at 
0 hours of infection, 24 hours, 48 hours, 72 hours or 96 hours p.i. 100 mg/kg of drug was given once a 
day for 14 days. Two animals in each group were sacrificed at day 7 to measure objective morbidity; 
the remainder of the animals were used to calculate survival rates. Animals in the placebo group, that 
were not given ST-246, showed signs of illness beginning on day 4 and all died between days 6–9. 
Signs of disease included lethargy, anorexia, nosebleeds, and terminal respiratory distress. At day 7, a 
sampling  of  placebo-treated  animals  exhibited  significant  leukocytosis,  transaminitis,  and 
coagulopathy;  almost  10
5  pfu/mL  of  infectious  monkeypox  was  found  in  blood;  at  this  time,  
between 10
7 and 10
8 pfu /mL of infectious MPXV was observed in 10% organ homogenates of liver, 
spleen and lung. Animals treated on days 0, 24, 48 or 72 hours, before symptomatic disease onset, all 
survived infection and showed no signs of disease. At day 7, in a sampling of animals treated at  
hour 0, 24, 48 or 72 p.i., no virus was found in the liver, spleen, lung, or blood; although some 
abnormal  values  were  apparently  recorded,  no  clear  trends  in  leukocytosis,  transaminitis  or 
coagulopathy were noted with delay in treatment onset. In animals initiating treatment at 96 hours p.i., 
concurrent with symptomatic disease onset, 67% of animals survived infection. 2/4 survivors showed 
signs of disease. In those animals that succumbed to infection, ST-246 prolonged the time to death; the 
mean time to death was day 7 for animals receiving placebo and day 13 for those receiving ST-246 in 
the 96 hour p.i. treatment group. The sampling of animals at day 7, initiating ST-246 at 96 hour p.i., 
demonstrated lower levels of viremia (~3 log decrease) and ~5 logs less virus in liver, spleen and lungs 
than that seen on the placebo treated animals at day 7. Although some evidence of transaminitis was 
present,  leukocytosis  and  coagulopathy  were  not  observed  in  this  treatment  group.  Pathologic 
examination of tissues in general showed greater tissue necrosis in animals treated at later times p.i. 
This study was able to demonstrate a survival benefit in animals treated prior to, or at the onset of 
disease symptoms, in a disease model that has a time course attenuated with respect to what is seen in 
human disease.  Viruses 2010, 2                         
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Table 1. Animal models using monkeypox virus (MPXV) as a challenge virus. 
  Genetic 
Diversity 
Immuno-
reagent 
Availability 
MPXV 
Strain 
Used 
Inoculation 
Route 
Dosage 
Used 
(pfu) 
Days until 
Symptoms 
Rash 
Development 
(days) 
LD50  Mortality 
(%) 
Time to 
Death 
Guinea pigs [2]  Outbred  Medium  WA  Intracardiac, IN, 
oral or FP 
Not 
provided  NA  No rash  NA  0  NA 
Golden 
hamsters
 [2]  Outbred  Medium  WA  Intracardiac, oral, 
IN, scarified skin 
1.5–
5.9 × 10
7  NA  No rash  NA  0  NA 
Adult rabbits [2]  Outbred  High  WA 
IV  10
7  5–6 
Extensive 
disseminated 
rash 
__  8 
One animal 
died one 
month post 
infection 
due to 
cachexia 
Scarified 
skin/intradermal  10
5  Not 
provided 
Localized 
lesion in 
addition to 
disseminated 
rash for some 
animals 
NA  0  NA 
Oral  >10
9  NA  No rash  NA  0  NA 
10 day old 
rabbits
 [2]  Outbred  High  WA 
Oral  10
6  4–6  Disseminated 
rash  __  85  4–14 days 
IN  10
6  Not 
provided  No rash  __  83  4–5 days 
Adult white rats 
[2]  Outbred  Medium  WA  IV, IN, cutaneous  10
1 to 
10
3  NA  No rash  NA  0  NA 
1–3 day old 
white rats
 [2]  Outbred  Medium  WA  IN  10
1 to 
10
3 
Not 
provided  No rash  __  100  5–6 days 
Cotton rats
 [6]   Outbred  Medium  WA 
IV  10
5  Not 
provided  Not provided  __  100  4–5 days 
IN  10
5  Not 
provided  Not provided  __  50  4–5 days 
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Table 1. Cont. 
  Genetic 
Diversity 
Immuno-
reagent 
Availability 
MPXV 
Strain 
Used 
Inoculation 
Route 
Dosage 
Used 
(pfu) 
Days until 
Symptoms 
Rash 
Development 
(days) 
LD50  Mortality 
(%) 
Time to 
Death 
Multimammate 
rats
 [8]   Outbred  Low  WA  IN, IP  Not 
provided 
Not 
provided  Not provided  __  Not 
provided 
Not 
provided 
Common 
squirrel
 [9] 
(Sciurus 
vulgaris) 
Outbred  Low  CB  IN, oral, 
scarification  10
6  1–5  No rash  __  100  7–8 days 
African 
squirrels (six 
species)
 [10]  
Outbred  Low  CB 
IN 
10
5, 10
6  Not 
provided  No rash  __  100  Not 
provided 
10–10
4  16–25 until 
rash 
Rash on non-
fur-bearing 
areas of skin 
in a few 
squirrels 
__ 
Varied 
based on 
squirrel 
species 
Not 
provided 
Oral  10
5  16–25 until 
rash 
Rash on non-
fur-bearing 
areas of skin 
in a few 
squirrels 
__  Not 
provided 
Not 
provided 
Cutaneous  10
5  Not 
provided 
Localized 
lesion at 
inoculation 
site 
__  Not 
provided 
Not 
provided 
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Table 1. Cont. 
  Genetic 
Diversity 
Immuno-
reagent 
Availability 
MPXV 
Strain 
Used 
Inoculation 
Route 
Dosage 
Used 
(pfu) 
Days until 
Symptoms 
Rash 
Development 
(days) 
LD50  Mortality 
(%) 
Time to 
Death 
Ground squirrel
 
[11,12]  Outbred  Low 
WA  IP, IN  10
5.1  4–5  No rash  __  100 
IP: 6–7 
days 
IN: 8–9 
days 
WA, 
CB  Subcutaneous  100  3–5  No rash  0.35 pfu CB 
0.46 pfu WA  100  6–11 days 
Prairie dogs 
[13–15]  Outbred  Low 
WA 
IP  10
5.1  4  No rash  __  100  8–11 days 
IN  10
5.1  4  Lesions on 
lips/tongue  __  60  11–14 days 
WA, 
CB 
IN  10
4.5  9–12 days 
until rash 
Disseminated 
rash 
WA: 
1.29 × 10
5 
pfu 
CB: 5.9 × 10
3 
pfu 
WA: 0 
CB: 25 
CB: 13 
days 
Scarification  10
4.5  9–12 days 
until rash 
Disseminated 
rash  __  WA: 0 
CB: 50 
CB: 11–12 
days 
8 day old white 
mice
 [2] 
Not 
specified  High  WA 
FP  6 × 10
2  Not 
provided  No rash  __  100  Not 
provided 
IP  1.2 × 10
6  Not 
provided  No rash  __  100  Not 
provided 
IN  1.2 × 10
6  Not 
provided  No rash  __  100  Not 
provided 
ID  1.2 × 10
6  Not 
provided  No rash  __  50  Not 
provided 
Oral  1.2 × 10
6  Not 
provided  No rash  __  40  Not 
provided 
12 day old white 
mice
 [2] 
Not 
specified  High  WA  Oral  1.2 × 10
6  Not 
provided  No rash  __  14  Not 
provided 
15 day old white 
mice
 [2] 
Not 
specified  High  WA  IN  1.2 × 10
6  Not 
provided  No rash  __  100  Not 
provided 
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Table 1. Cont. 
  Genetic 
Diversity 
Immuno-
reagent 
Availability 
MPXV 
Strain 
Used 
Inoculation 
Route 
Dosage 
Used 
(pfu) 
Days until 
Symptoms 
Rash 
Development 
(days) 
LD50  Mortality 
(%) 
Time to 
Death 
BALB/c and 
C57BL/6 lab 
mice
 [17] 
Inbred  High  WA, 
CB  IN, FP  10
5  6  No rash  NA  0  NA 
SCID BALB/c 
lab mice
 [18]  Inbred  High  WA, 
CB  IP  10
5  5–7  No rash  __  100  9–11 days 
C57BL/6stat-/- 
lab mice
 [19]  Inbred  High  CB  IN 
47 
No 
symptoms 
except 
weight loss 
No rash 
Females: 213 
pfu 
Males: 47 pfu 
25–50  12–21 days 
4700 
No 
symptoms 
except 
weight loss 
No rash 
Females: 213 
pfu 
Males: 47 pfu 
100  9 days 
CAST/EiJ 
wild-derived lab 
mice
 [20] 
Inbred  High 
CB 
IN  10
4  Not 
provided  No rash  680 pfu  100  8–10 days 
IP  10
3  Not 
provided  No rash  14 pfu  100  6–8 days 
WA  IN  10
4  Not 
provided  No rash  7600 pfu  50  9 days 
Dormice
 [16]  Outbred  Low  CB 
FP  1.4 × 10
4  Not 
provided  No rash  __  92  7–10 days 
IN  2  3  No rash  12 pfu  38  12.3 ± 5 
days 
IN  200–
2000  3 days  No rash  12 pfu  100  7.9 ± 1 and 
8.7 ± 1 Viruses 2010, 2                         
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Schultz  et  al.  infected  African  dormice  with  a  lethal  challenge  of  Congo  Basin  clade  virus  
MPXV-ZAI-79 via an IN route of infection to evaluate the efficacy of Cidofovir as post exposure 
prophylaxis  [16]. Four hours post intranasal  infection with 75, 4 × 10
3, or  5 × 10
3 pfu of MPXV, 
animals  were  intraperitoneally  administered  100  mg/kg  cidofovir  (the  calculated  LD50  for  the 
dormouse MPXV model was 12 pfu). Aggregate data from all challenges showed animals treated with 
cidofovir had a mortality rate of 19% (7/36), whereas vehicle treated animals all (41/41) succumbed to 
disease.  Treatment  initiation  at  later  times  p.i.  was  not  evaluated;  effects  on  viral  load  or 
histopathologic changes were not reported. 
As  inbred  mice  have  historically  shown  little  disease  symptomatology  or  pathogenesis  
post  monkeypox  infection,  Stabenow  et  al.  utilized  a  laboratory  mouse  strain  lacking  STAT1 
(C57BL/6stat-/-), which has been found to be sensitive to a range of viruses including SARS, murine 
norovirus 1, respiratory viruses, dengue virus and MPXV [19,22–25]. These animals are deficient in 
their ability to transcribe many of the Type I and Type II receptor interferon response genes. The 
authors used the Congo Basin clade virus MPX-ZAI-79, evaluated disease and the protective efficacy 
of CMX001 and ST246. In untreated mice, 0% mortality was observed with 4.7 pfu challenge, 90% 
mortality with 470 pfu of virus and 100% mortality with 4,700 pfu. Over 25% total body weight loss, 
and mortality was observed on or prior to day 10 p.i. in untreated animals. Animals in the treatment 
studies were subsequently challenged with 5,000 pfu via an IN infection. Animals were then treated 
with 10 mg/kg of CMX001 by gastric gavage on the day of challenge followed by every other day with 
2.5 mg/kg until day 14 p.i. All C57BL/6 stat-/- mice that were treated with drug survived infection, 
demonstrated <10% body weight loss between days 10 and 20, and developed a serologic response to 
monkeypox. Similarly, mice treated daily, starting at the day of virus challenge, with 100mg/kg of 
ST246 for 10 days also survived infection and manifest <10% body weight loss between days 10 and 
20.  In  this  system,  antiviral  treated  animals  rechallenged  with  monkeypox  at  day  38  post  initial 
infection  (at  least  10  days  post  reinitiation  of  steady  weight  gain),  manifest  20%  mortality.  The 
model—again one with a short disease course—is useful for demonstrating immediate post exposure 
efficacy of antiviral treatment in the absence of a functioning interferon response system. Additionally, 
in this animal model system, perhaps due to the immune defect, a monkeypox protective immune 
response was not elicited in all animals receiving antiviral treatment. This observation merits further 
observation in other animal model systems.  
Smith et al. tested the efficacy of ST246 in a prairie dog MPXV model [26]. MPXV challenged 
prairie dogs have previously been shown to have an asymptomatic period followed by symptoms of 
disease including lethargy, nasal discharge, inappetence, weight loss and systemic lesion development 
most commonly between days 9–12. In the current study, animals were inoculated via an IN challenge 
with the Congo Basin clade virus ROC-2003-358. This is a different strain of MPXV than that used in 
the previous described studies, but is also a strain belonging to the Congo Basin clade. The challenge 
dose was 3.8 × 10
5, equal to 65 × LD50 for the prairie dog model. Animals were divided into three 
treatment groups; prophylactic (day 0), post exposure (day 3) and therapeutic (varying day based on 
rash onset), and a control vehicle treated group. ST246 was formulated at 30 mg/mL and administered 
daily, by oral gavage, for 14 days. Animals initiating treatment at day 0 or 3 were protected from death 
and  apparent  signs of illness.  Animals treated at rash onset  had symptoms  similar to the placebo 
control group; however symptoms were less severe in the treated animals. Although all animals treated Viruses 2010, 2                         
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at rash onset survived infection, animals lost 10–24% of body weight and did develop generalized rash 
(however, lesions resolved more quickly when compared to untreated prairie dogs in previous studies 
[13,14]. Although asymptomatic, viable virus was shed sporadically from animals in the prophylaxis 
and post exposure groups (from two oropharyngeal samples in the day 0 prophylaxis group, and five 
samples from the day 3 post exposure group). More, sustained virus was detected in the oropharyngeal 
samplings of the animals in the therapeutic treatment group, but levels were less than the virus levels 
in the untreated group. 1/4 sham-treated animals survived infection. Signs of disease and viral titers 
were all increased in this group of animals compared to the animals treated with ST-246. This is the 
first small animal study where a treatment and survival benefit has been demonstrated when animals 
are treated at later stages of illness. Initiation of treatment at rash onset is similar to expectations of a 
human  treatment  regimen.  The  observation  of  virus  shedding  after  treatment  cessation  in  the 
prophylactically or post exposure treated animals merits further study to assess whether this reflects 
viral resistance or a blunted and delayed immune recognition and ultimate clearance of virus.  
4. Discussion 
Animal models permit an advance beyond what can be gleaned from tissue culture evaluation of an 
antiviral effect. The evaluation of an antiviral, in the context of a host with a functioning immune 
system, enables better understanding of therapeutics’ potential efficacy. The evaluation of an antiviral 
in the context of an impaired immune system enables better understanding of therapeutic use in a 
particular  immunosuppressed  population.  Pathogen  host  range,  especially  if  not  a  simple  issue  of 
receptor utilization, can confound the ability to interpret, and extrapolate to the human, some of the 
nuances of the host pathogen interaction and prediction of potential human therapeutic benefit. Of the 
small animal models used to evaluate antiviral efficacy, all have used stringent virus challenges (all 
greater  than  10  ×  LD50)  and  shown  survival  benefit.  Routes  of  infection  have  used  methods  that 
attempt to simulate potential human routes of infection and resultant human illness courses. Given the 
uncertainties of what a human infectious or lethal monkeypox dose is, it is difficult to extrapolate the 
potential ―best fit‖ of any of these models for human disease. The clinical time course of disease in the 
prairie dog model, however, has a temporal relationship that is close to what has been described with 
human systemic orthopoxvirus (variola or monkeypox) disease. However, a limitation of the prairie 
dog and some of the other described animal systems, with the exception of the mouse model, is a 
paucity of immune reagents. There are a handful of antiviral compounds which show promise in these 
small animal models using monkeypox virus as the challenge. Additional studies evaluating treatment 
benefit when used in later stages of disease, their effect on elicitation of a protective immune response, 
evaluation of antiviral resistance, and their effect on viral shedding will improve our understanding of 
how they may be used in treatment of human disease, or in response to epidemic disease.  
Disclaimer  
The  findings  and  conclusions  in  this  report  are  those  of  the  author(s)  and  do  not  necessarily 
represent the official position of the Centers for Disease Control and Prevention. Viruses 2010, 2                         
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